[go: up one dir, main page]

WO1992011037A3 - Ciblage d'agents therapeutiques au moyen de polysaccharides - Google Patents

Ciblage d'agents therapeutiques au moyen de polysaccharides Download PDF

Info

Publication number
WO1992011037A3
WO1992011037A3 PCT/US1991/009368 US9109368W WO9211037A3 WO 1992011037 A3 WO1992011037 A3 WO 1992011037A3 US 9109368 W US9109368 W US 9109368W WO 9211037 A3 WO9211037 A3 WO 9211037A3
Authority
WO
WIPO (PCT)
Prior art keywords
targeting
therapeutic agent
polysaccharides
complex
therapeutic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/009368
Other languages
English (en)
Other versions
WO1992011037A2 (fr
Inventor
Lee Josephson
Ernest V Groman
Chu Jung
Jerome M Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amag Pharmaceuticals Inc
Original Assignee
Advanced Magnetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Magnetics Inc filed Critical Advanced Magnetics Inc
Priority to JP50317792A priority Critical patent/JP3357362B2/ja
Priority to EP92902979A priority patent/EP0563249B1/fr
Priority to DE69125848T priority patent/DE69125848T2/de
Priority to DK92902979.1T priority patent/DK0563249T3/da
Publication of WO1992011037A2 publication Critical patent/WO1992011037A2/fr
Publication of WO1992011037A3 publication Critical patent/WO1992011037A3/fr
Anticipated expiration legal-status Critical
Priority to GR940300001T priority patent/GR940300001T1/el
Priority to GR970401010T priority patent/GR3023358T3/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention se rapporte à un procédé servant à cibler un agent thérapeutique sur une population cellulaire spécifique, selon lequel un complexe est formé entre l'agent thérapeutique et un polysaccharide susceptible d'interagir avec un récepteur cellulaire, et le complexe qui en résulte est absorbé par la cellule par endocytose induite par récepteur (EMR). Selon un mode de réalisation, un complexe d'un agent thérapeutique contenant du fer et le polysaccharide arabinozalactane peut être formé et utilisé pour fournir du fer par EMR spécifiquement à des hépatocytes.
PCT/US1991/009368 1990-12-19 1991-12-13 Ciblage d'agents therapeutiques au moyen de polysaccharides Ceased WO1992011037A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP50317792A JP3357362B2 (ja) 1990-12-19 1991-12-13 多糖類を用いる治療薬のターゲティング
EP92902979A EP0563249B1 (fr) 1990-12-19 1991-12-13 Ciblage d'agents therapeutiques au moyen de polysaccharides
DE69125848T DE69125848T2 (de) 1990-12-19 1991-12-13 Targeting von therapeutischen mitteln durch verwendung von polysacchariden
DK92902979.1T DK0563249T3 (da) 1990-12-19 1991-12-13 Målretning af terapeutiske midler under anvendelse af polysaccharider
GR940300001T GR940300001T1 (en) 1990-12-19 1994-02-28 Targeting of therapeutic agents using polysaccharides
GR970401010T GR3023358T3 (en) 1990-12-19 1997-05-09 Targeting of therapeutic agents using polysaccharides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63001790A 1990-12-19 1990-12-19
US630,017 1990-12-19

Publications (2)

Publication Number Publication Date
WO1992011037A2 WO1992011037A2 (fr) 1992-07-09
WO1992011037A3 true WO1992011037A3 (fr) 1992-08-06

Family

ID=24525421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/009368 Ceased WO1992011037A2 (fr) 1990-12-19 1991-12-13 Ciblage d'agents therapeutiques au moyen de polysaccharides

Country Status (9)

Country Link
EP (1) EP0563249B1 (fr)
JP (1) JP3357362B2 (fr)
AT (1) ATE151991T1 (fr)
CA (1) CA2097589C (fr)
DE (2) DE563249T1 (fr)
DK (1) DK0563249T3 (fr)
ES (1) ES2059299T3 (fr)
GR (2) GR940300001T1 (fr)
WO (1) WO1992011037A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5490991A (en) * 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
US5554386A (en) * 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
GB9119762D0 (en) * 1991-09-16 1991-10-30 Filler Aaron G Particulate agents for nmt
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
PT101422B (pt) * 1993-12-06 1997-06-30 Ineti Inst Biotec Q F E Tecnol Formulacoes lipossomicas contendo vidarabina e/ou derivados, com indice terapeutico elevado e processo para a sua preparacao
GB9600427D0 (en) * 1996-01-10 1996-03-13 Nycomed Imaging As Contrast media
HUP9901192A3 (en) 1996-01-10 2000-02-28 Amersham Health As Contrast media
FR2755976B1 (fr) 1996-11-15 1999-01-15 Idm Immuno Designed Molecules Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
IL142432A0 (en) 1998-10-05 2002-03-10 Penn State Res Found Compositions and methods for enhancing receptor-mediated cellular internalization
EP1181571B1 (fr) * 1999-05-21 2008-12-17 GE Healthcare AS Procede d'imagerie par resonance magnetique
GB9921579D0 (fr) * 1999-09-13 1999-11-17 Nycomed Imaging As
US7082326B2 (en) 2000-03-31 2006-07-25 Amersham Health As Method of magnetic resonance imaging
CN1095472C (zh) * 2000-04-17 2002-12-04 上海复康医药科技发展有限公司 叶酸－多聚糖复合物，其制备方法和以该复合物为活性成分的药物组合物
IT1319665B1 (it) * 2000-11-17 2003-10-23 Pharma Biotech Ltd Addotti di corticosteroidi con polimeri polisaccaridici naturali.
DE10209822A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
JP4927536B2 (ja) * 2004-03-05 2012-05-09 電気化学工業株式会社 ヒアルロン酸−メトトレキサート結合体
US7807675B2 (en) * 2004-04-02 2010-10-05 Denki Kagaku Kogyo Kabushiki Kaisha Hyaluronic acid-methotrexate conjugate
JP2013053103A (ja) * 2011-09-05 2013-03-21 Ltt Bio-Pharma Co Ltd 薬物を封入した肝臓集積性ナノ粒子

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281809A2 (fr) * 1987-03-09 1988-09-14 American Cyanamid Company Compositions à libération retardée administrables par voie parentérale et leurs utilisations
WO1990001295A1 (fr) * 1988-08-04 1990-02-22 Advanced Magnetics, Incorporated Agents de contraste d'irm de type endocytose induits par recepteur

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281809A2 (fr) * 1987-03-09 1988-09-14 American Cyanamid Company Compositions à libération retardée administrables par voie parentérale et leurs utilisations
WO1990001295A1 (fr) * 1988-08-04 1990-02-22 Advanced Magnetics, Incorporated Agents de contraste d'irm de type endocytose induits par recepteur

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Biochemistry International, vol. 10, no. 3, March 1985, (North Ryde, AU), P. DASGUPTA et al. "Receptor-mediated uptake of asialoganglioside liposomes: Sub-cellular distribution on the liposomal marker in isolated liver cell types", pages 327-338, see page 327, summary *
Carbohydrate Research, vol. 118, 1983, (Amsterdam, NL), M.M. PONPIPOM et al.: "Synthesis of 6-(5-cholesten-3beta-yloxy)hexyl 4-O-(6-deoxy-beta-D-galactopyranosyl)-1-thio-beta-D-glucopyranoside and derivatives thereof for in vivo liposome studies", pages 47-55, see page 47, paragraph 1 - page 48, paragraph 1 *
J. American medical Association, vol. 243, no. 17, 2 May 1980, (Chicago, IL, US), R.D. HAMSTRA et al.: "Intravenous iron dextran in clinical medicine", pages 1726-1731, see page 1726, abstract (cited in the application) *
Magnetic Resonance Imaging, vol. 8, no. 5, 1990, (Elmsford, NY, US), L. JOSEPHSON et al.: "A funtionalized superparamagnetic iron oxide colloid as a receptor directed MR contrast agent", pages 637-646, see whole article, and in particular page 644, last paragraph - page 645, paragraph 1 (cited in the application) *
Methods in Enzymology, vol. 112, 1985, (New York, US), J.L. BODMER et al.: "[23] Carrier potential of glycoproteins", pages 298-306, see page 298, paragraph 2; page 302, paragraph 2 (cited in the application) *
Pharmaceutical Research, vol. 6, no. 2, 1989, (Stuttgart, DE), D.K.F. MEIJER et al.: "Covalent and noncovalent protein binding of drugs: Implications for hepatic clearance, storage, and cell-specific drug delivery", pages 105-118, see page 105, abstract; page 113, table II (cited in the application) *
Proc. Indian. natn. Sci. Acad., vol. 48, supplement no. 1, 1982, (New Delhi, IN), P. GHOSH et al.: "An approach to tissue targeting of drugs and proteins using liposomes", pages 12-19, see page 12, abstract *
Science, vol. 244, 12 May 1989, (Washington, DC, US), A. MUKHOPADHYAY et al.: "Receptor-mediated drug delivery to macrophages in chemotherapy of Leishmaniasis", pages 705-707, see page 705, abstract (cited in the application) *
The Journal of Biological Chemistry, vol. 263, no. 29, 15 October 1988, (Baltimore, US), G.Y. WU et al.: "Receptor-mediated gene delivery and expression in vivo", pages 14621-14624, see page 14621, abstract (cited in the application) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein

Also Published As

Publication number Publication date
JPH06503347A (ja) 1994-04-14
JP3357362B2 (ja) 2002-12-16
CA2097589A1 (fr) 1992-06-20
GR3023358T3 (en) 1997-08-29
CA2097589C (fr) 1998-05-05
ES2059299T1 (es) 1994-11-16
ATE151991T1 (de) 1997-05-15
ES2059299T3 (es) 1997-10-01
WO1992011037A2 (fr) 1992-07-09
EP0563249B1 (fr) 1997-04-23
GR940300001T1 (en) 1994-02-28
EP0563249A1 (fr) 1993-10-06
DK0563249T3 (da) 1997-11-03
DE563249T1 (de) 1994-03-03
DE69125848T2 (de) 1997-07-31
DE69125848D1 (de) 1997-05-28

Similar Documents

Publication Publication Date Title
WO1992011037A3 (fr) Ciblage d'agents therapeutiques au moyen de polysaccharides
EP0771147A4 (fr) Compositions et procedes pour accroitre l'immunite de cellules tumorales in vivo
GB2017105B (en) Method of preparing enzyme conjugates their use and coupling agents for use in the method
FI982303A0 (fi) Menetelmä terapeuttisesti aktiivisten, makrosyklisten bifunktionaalisten kelaatinmuodostajien komplekseja sisältävien vasta-ainekonjugaattien valmistamiseksi
MY109310A (en) Antimicrobial method and formulation employing type ii endoglucosidase and antimicrobial agent
WO2001005433A3 (fr) Methodes et compositions pour la liberation et la retention d'agents actifs dans des ganglions lymphatiques
IL129445A0 (en) Improvements in or relating to diagnostic/therapeutic agents
AU2276195A (en) Electrotransport system with enhanced drug delivery
AU2001269688A1 (en) Combination containing an antifolate and methylmalonic acid lowering agent
MY108864A (en) Peptide-carbohydrate conjugates generating t-cell immunity
GB9415167D0 (en) Improvements relating to cancer therapy
ATE60900T1 (de) Tensidepraeparate.
MY106109A (en) 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions
WO1991018027A3 (fr) Composes
WO1997023240A3 (fr) Conjugue comprenant un principe actif, un polypeptide et un polyether
MX9606559A (es) Terapia para el cancer usando linfotoxina.
GB9905663D0 (en) Iodine preparation composition
AU543499B2 (en) Producing hydrogen and injecting into direct reduction furnaces or blast furnaces
AU9365598A (en) Prostate radiotherapy apparatus
ZA9915B (en) Use of oxidation promoting chemicals in the oxidation of oxidizable galactose type of alcohol configuration containing polymer.
NZ335514A (en) oxidation dyeing composition for keratin fibres containing 2-amino-3-hydroxy-pyridine and an oxidoreductase enzyme and dyeing process using this composition
YU180791A (sh) Injekcioni proizvod za sitni pesak i druge porozne materijale
WO1993020852A3 (fr) Agents de chelation macrocycliques, leurs chelates et conjugues
Candlin Principles and practice in communicative language teaching
AU4193800A (en) Use of tagatose to enhance key blood factors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP NO

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP NO

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2097589

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992902979

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992902979

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1992902979

Country of ref document: EP